Funding for Medical Research
and Clinical Trials
and Clinical Trials
Funding Details for Neurological
Use the contact information shown for the organization to apply for the funding.
Please notify CenTrial of any offer is incorrect or has expired.
Please notify CenTrial of any offer is incorrect or has expired.
Angelman Syndrome
Angelman Syndrome Foundation (ASF)
Type of Organization: Foundation
Email Address: amoore@angelman.org
Funds Available for Clinical Trials: ✗ Research: ✔
All proposals, including cover letters, should be submitted in one .pdf file using the ASF Grant Submission Form.
If you experience a problem downloading the form, open this page in a different browser or an incognito window.
Questions should be directed to ASF Scientific Advisory Chair at: research@angelman.org.
1.
Name of Proposal File
The file name of the pdf should be:
PI’s last name_MM_20XX_Gen_RFP.pdf
(e.g., Smith_10_2021_Gen_RFP.pdf)
2.
Details to Include in Proposal
Cover page including title of proposal and name of principal investigator
One-page summary abstract of proposed research
Proposal, including hypothesis, background, research plan, and significance of the proposed research; page limits indicated within application
Curriculum vitae of the applicant
One-page detailed budget. Indirect costs of up to 10% will be allowed (to be included in the total budget amount not to exceed $100,000 per year)
Proposals involving human or animal subjects must be approved by institutional review boards before funding is released. Please include approval with proposal if possible.
3.
Submit Proposal Via Email
Attach your proposal to an email sent to amoore@angelman.org with the subject line to read:
ASF MM_20XX General RFP Submission
(e.g., ASF 10_2021 General RFP Submission)
Other info: The ASF Scientific Advisory Committee identified the following areas of unmet need in AS research. Priority will be given to the following topics:
Projects studying or correcting the heterozygous effect of non-UBE3A genes in deletion.
Projects studying the potential results of increasing UBE3A after therapies or for some subtypes of AS.
Projects studying delivery of therapies and potential for improvement.
Symptomatic therapies that impact the daily life of people with Angelman syndrome and their families.
Proposals that do not address these topics are still welcome and will be given full consideration.
Angelman Syndrome Foundation (ASF)
Type of Organization: Foundation
Email Address: amoore@angelman.org
Funds Available for Clinical Trials: ✗ Research: ✔
Funding Details
Requirements: Instructions For SubmissionAll proposals, including cover letters, should be submitted in one .pdf file using the ASF Grant Submission Form.
If you experience a problem downloading the form, open this page in a different browser or an incognito window.
Questions should be directed to ASF Scientific Advisory Chair at: research@angelman.org.
1.
Name of Proposal File
The file name of the pdf should be:
PI’s last name_MM_20XX_Gen_RFP.pdf
(e.g., Smith_10_2021_Gen_RFP.pdf)
2.
Details to Include in Proposal
Cover page including title of proposal and name of principal investigator
One-page summary abstract of proposed research
Proposal, including hypothesis, background, research plan, and significance of the proposed research; page limits indicated within application
Curriculum vitae of the applicant
One-page detailed budget. Indirect costs of up to 10% will be allowed (to be included in the total budget amount not to exceed $100,000 per year)
Proposals involving human or animal subjects must be approved by institutional review boards before funding is released. Please include approval with proposal if possible.
3.
Submit Proposal Via Email
Attach your proposal to an email sent to amoore@angelman.org with the subject line to read:
ASF MM_20XX General RFP Submission
(e.g., ASF 10_2021 General RFP Submission)
Other info: The ASF Scientific Advisory Committee identified the following areas of unmet need in AS research. Priority will be given to the following topics:
Projects studying or correcting the heterozygous effect of non-UBE3A genes in deletion.
Projects studying the potential results of increasing UBE3A after therapies or for some subtypes of AS.
Projects studying delivery of therapies and potential for improvement.
Symptomatic therapies that impact the daily life of people with Angelman syndrome and their families.
Proposals that do not address these topics are still welcome and will be given full consideration.